pocketful logo light
pocketful logo light
Divis Laboratories Ltd logo

Divis Laboratories Ltd

NSE: DIVISLAB BSE: 532488

₹6638.50

(1.70%)

Fri, 19 Jun 2026, 09:48 am

mtf coin illustrationMTF 5x

Divis Laboratories Share Price Live Chart

1 Day

(1.70%)

No Result Found

Summary

  • Market Cap (in Cr)

    176807.38

  • Net Profit (in Cr)

    2191

  • P/B

    10.22

  • Sector P/E

    33.76

  • P/E

    69.82

  • EV/EBITDA

    44.95

  • Debt/Equity (Industry)

    0.17

  • Interest Cover (Industry)

    18.17

  • ROCE (Industry)

    20.59

  • RONW (Industry)

    17.62

  • ROE

    15.35

  • ROCE

    20.42

  • Debt/Equity

    0

  • EPS (TTM)

    98.81

  • Dividend Yield

    0.45

  • Book Value

    631.38

  • Interest Cover

    973

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.8851.8851.8951.8951.89
FII20.2920.0819.3919.7418.01
DII19.2219.2819.7619.0520.71
Public8.608.768.969.329.39
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

54.34

MACD

25.74

50 DMA

6568.18

200 DMA

6347.52

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic7675.177190.676928.836706.176444.336221.675737.17
Fibonacci7190.677005.596891.256706.176521.096406.756221.67
Camarilla6800.246755.826711.416706.176622.596578.186533.76

Pivots Level: Classic

R3

+969

7675.17

R2

+484.50

7190.67

R1

+222.67

6928.83

6706.17
6706.17
Pivot Point
LTP: 6730

S1

-261.83

6444.33

S2

-484.50

6221.67

S3

-969

5737.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    6685.79

  • 20-EMA

    6671.78

  • 30-EMA

    6644.17

  • 50-EMA

    6575.43

  • 100-EMA

    6468.89

  • 200-EMA

    6357.54

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
23 May 2026board-meetingsAccounts, Quarterly Results, Dividend
23 May 2026agm
11 Feb 2026board-meetingsQuarterly Results, Nine Months Results
07 Nov 2025board-meetingsQuarterly Results
25 Jun 2025dividendFinal Dividend - Rs. - 3025 Jul 2025
17 May 2025agm
17 May 2025dividend₹30.00 Dividend /Share25 Jul 2025
02 Jul 2024dividendFinal Dividend - Rs. - 3002 Aug 2024
25 May 2024dividend₹30.00 Dividend /Share02 Aug 2024
25 May 2024agm

Read More

Peer Comparison

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Read More

Divis Laboratories Ltd About

Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Ramesh B V Nimmagadda

Employees

Contact

Website icon

Website

http://www.divislabs.com

Email icon

Email

mail@divislaboratories.com; cs@divislaboratories.c

Phone icon

Phone

91-40-23786300/23786352/400

Location icon

Location

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Read More

Divis Laboratories Ltd Company History

YearHistory
2019
  • Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II.
  • The 7th USFDA inspection in Unit 2 took place.
2020
  • Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred.
  • US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place.
  • Commencement of commercial production from DCV-SEZ Unit began.
  • Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021
  • Ground breaking of the manufacturing plant in Kakinada took place.
2022
  • Divi's Laboratories received the EHS excellence Award.
  • Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024
  • Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy331086120.509 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell331086120.509 Oct 2025
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849blockBuy21874683514 Jul 2025
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828blockSell21874683514 Jul 2025
PI OPPORTUNITIES AIF V LLPblockBuy803245979.6506 Nov 2024
PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITEDblockSell803245979.6506 Nov 2024
NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUNDblockBuy434783637.720 Oct 2023
RONDURE NEW WORLD FUNDblockSell434783637.720 Oct 2023
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell2091243271.414 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy2091243271.414 Nov 2022

Read More

Divis Laboratories Ltd News

Divis Labs sets ₹30 dividend, TDS details

Divi's Laboratories recommended a ₹30 per share dividend for FY26. The company outlined TDS rates and documentation for residents and non-residents.

11 Jun 2026

companies

Divi's Labs Board Meet on May 23 to Approve FY26 Results

Divi's Laboratories has scheduled a Board meeting on May 23, 2026, to approve audited standalone and consolidated financial results for Q4 and FY26, and to consider dividend recommendation.

14 May 2026

companies

Divi's Labs Submits Q4FY26 Compliance Certificate

Divi's Laboratories Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026, confirming proper dematerialization processes.

06 Apr 2026

companies

Divi's Lab Gets ₹570.51 Cr Tax Assessment Order for FY23

Divi's Laboratories receives draft tax assessment order proposing ₹570.51 crore additions for FY2022-23, primarily related to transfer pricing and corporate tax adjustments. Company plans to appeal.

21 Mar 2026

companies

Divi's Labs Receives Draft Tax Assessment Order

Divi's Laboratories receives draft assessment order from Income Tax Authority proposing additions of Rs.570.51 crores for FY2022-23, primarily related to transfer pricing adjustments.

21 Mar 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number